FDA OKs Oxoid's rapid antimicrobial susceptibility test:
This article was originally published in Clinica
Oxoid has received US FDA 510(k) clearance to market its antimicrobial susceptibility test for detecting oxacillin/methicillin resistance. The PBP2' test, which identifies MRSA and MRCoNS, is the first rapid latex test to gain the nod in the US for confirming both Staphylococcus aureus and coagulase negative staphylococci, claims the Basingstoke, UK firm. Moreover, the company adds, the PBP2' test has demonstrated an accuracy of 100% compared with PCR.
You may also be interested in...
Perrigo, Pfizer want the US FDA to postpone its March 1 deadline for conducting nitrosamine risk assessments. Generics exec cites“serious compliance challenges” in conducting these assessments due to difficulty in finding the right lab equipment necessary to quantify nitrosamine daily intake limits.
Deal snapshot: For $425m up front, the pharma obtains a Phase III recombination fusion protein that shows ability to improve hospitalized patients’ clinical status and reduce risk of death.
Previous businesses FDA warned about COVID-19 claims for chlorine dioxide, a bleach solution, were marketing dietary supplements unlawfully. But Pro Breath MD's oral rinses available under the Dentist Select and OraCare brands are allowed and FDA isn’t asking the firm to discontinue distribution.